Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019)
Puma Biotechnology's (PBYI) quarterly Receivables - Other came in at $9.9 million in Q1 2019, up 743.57% on a QoQ basis from $1.2 million in Q4 2018.
Analysis
Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019) Analysis & Trends
Puma Biotechnology (PBYI) has 5 years of Receivables - Other data on file, last reported at $9.9 million in Q1 2019.
- Quarterly Receivables - Other changed N/A year-over-year to $9.9 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $9.9 million (changed N/A YoY) and the FY2018 annual result came in at $1.2 million, changed N/A from the prior year.
- Receivables - Other rose to $9.9 million in Q1 2019, from $1.2 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $11.2 million in Q3 2018 to a low of $1.2 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 486.99 Mn | 393.08 Mn | 44.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | 9.91 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Sep 30, 2018 | 11.23 Mn |
| Sep 30, 2014 | 1.76 Mn |
| Jun 30, 2014 | 1.76 Mn |
| Mar 31, 2014 | 13.30 Mn |
| Dec 31, 2013 | -1.48 Mn |
| Sep 30, 2013 | 11.29 Mn |
| Jun 30, 2013 | 14.77 Mn |
| Mar 31, 2013 | 17.34 Mn |
| Dec 31, 2012 | 10.61 Mn |